Home > Insider Trading > Filing (0001354488-13-005551)

Filing Details

Accession Number:: 0001354488-13-005551
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-10-03 16:49:25
Reporting Period:: 2013-10-01

Filing Date:: 2013-10-03
Accepted Time:: 2013-10-03 16:49:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1024126	Pernix Therapeutics Holdings Inc.	PTX	Pharmaceutical Preparations (2834)	330724736

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1485508	C. Cooper Collins	33219 Forest West Dr Magnolia TX 77354	Chief Strategic Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-10-01	27,736	$2.61	6,602,310	No	4	S	Direct
Common Stock	Disposition	2013-10-02	13,200	$2.57	6,589,110	No	4	S	Direct
Common Stock	Disposition	2013-10-03	25,700	$2.46	6,563,410	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	245,163	Indirect	Spouse
Common Stock	390,681	Indirect	GRAT
Common Stock	390,681	Indirect	Spousal GRAT

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/26/13.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.67, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.51 to $2.61, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.42 to $2.54, inclusive. The reporting person undertakes to provide to Pernix Therapeutics Holdings, Inc., any security holder of Pernix Therapeutics Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.